Want to see MLTX full AI Analyst Report?
MLTX Stock Chart & Stats
$18.34
-$0.83(-1.65%)
At close: 4:00 PM EST
$18.34
-$0.83(-1.65%)
Day’s Range― - ―
52-Week Range$5.95 - $62.75
Previous CloseN/A
Volume45.38K
Average Volume (3M)1.20M
Market Cap
$1.65B
Enterprise Value$1.21B
Total Cash (Recent Filing)$357.92M
Total Debt (Recent Filing)$100.80M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Aug 12, 2026EPS Estimate
-0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.88
Shares Outstanding82,615,395
10 Day Avg. Volume1,204,549
30 Day Avg. Volume1,203,803
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)2.79
Price to Sales (P/S)0.00
P/FCF Ratio-4.33
Enterprise Value/Market Cap0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-519.67
Enterprise Value/Ebitda-4.94
Forecast
1Y Price Target
$34.44Price Target Upside87.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.83
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Phase 3 Efficacy For Sonelokimab (HS)Durable, high-response Phase 3 results in adults (and strong adolescent signals) establish sonelokimab as a potentially best-in-class HS therapy. Robust efficacy plus a favorable safety profile materially strengthens commercial prospects, formulary positioning, and lasting competitive differentiation once approved.
Positive FDA Pre-BLA Outcome And Clear Submission PlanA constructive FDA pre-BLA meeting materially de-risks the regulatory pathway and gives clear timing for a BLA. Agreement on key trials and label scope (including adolescents) increases likelihood of approval and gives management visibility to plan manufacturing, commercial buildout, and payer engagement ahead of a potential 2027 launch.
Secured Long-term Manufacturing With Vetter PharmaA binding manufacturing partnership that reserves fill/finish capacity reduces execution risk at launch and supports scale-up. Having a named CMO with capacity committed improves time-to-market reliability, quality control, and commercial readiness—key operational strengths for a product-centric biotech entering commercialization.
Bears Say
No Revenue And Large, Persistent LossesAs a pre-commercial biotech, the company records no product revenue while reporting widening losses that translate into real cash outflows. This structural lack of operating income means long-term sustainability depends on successful approvals/commercialization or continuous financing, exposing strategic and execution risk until revenue is established.
Rising Debt And Higher LeverageGrowing reliance on debt raises interest, covenant, and refinancing risks that reduce strategic optionality. Higher leverage limits flexibility to fund additional trials or commercialization investments, and in adverse market conditions could force cost cuts, asset sales, or unfavorable partner deals, undermining long-term execution.
Dependence On Capital Raises And Dilution RiskFrequent reliance on equity offerings for runway is a structural risk for pre-revenue companies: it dilutes existing holders and links operational viability to volatile capital markets. Continued financing needs can pressure governance, pricing power, and long-term investor returns if commercial milestones are delayed or execution missteps occur.
MoonLake Immunotherapeutics News
MLTX FAQ
What was Moonlake Immunotherapeutics’s price range in the past 12 months?
Moonlake Immunotherapeutics lowest stock price was $5.95 and its highest was $62.75 in the past 12 months.
What is Moonlake Immunotherapeutics’s market cap?
Moonlake Immunotherapeutics’s market cap is $1.65B.
When is Moonlake Immunotherapeutics’s upcoming earnings report date?
Moonlake Immunotherapeutics’s upcoming earnings report date is Aug 12, 2026 which is in 32 days.
How were Moonlake Immunotherapeutics’s earnings last quarter?
Moonlake Immunotherapeutics released its earnings results on May 10, 2026. The company reported -$0.98 earnings per share for the quarter, missing the consensus estimate of -$0.892 by -$0.088.
Is Moonlake Immunotherapeutics overvalued?
According to Wall Street analysts Moonlake Immunotherapeutics’s price is currently Undervalued.
Does Moonlake Immunotherapeutics pay dividends?
Moonlake Immunotherapeutics does not currently pay dividends.
What is Moonlake Immunotherapeutics’s EPS estimate?
Moonlake Immunotherapeutics’s EPS estimate is -0.92.
How many shares outstanding does Moonlake Immunotherapeutics have?
Moonlake Immunotherapeutics has 82,615,395 shares outstanding.
What happened to Moonlake Immunotherapeutics’s price movement after its last earnings report?
Moonlake Immunotherapeutics reported an EPS of -$0.98 in its last earnings report, missing expectations of -$0.892. Following the earnings report the stock price went up 4.541%.
Which hedge fund is a major shareholder of Moonlake Immunotherapeutics?
Currently, no hedge funds are holding shares in MLTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MoonLake Immunotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$34.44 (87.81% Upside)
$34.44 (87.81% Upside)
Blogger Sentiment
Bullish
MLTX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 52.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 4.8%
Last 30 Days ▲ 4.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-58.71%
12-Months-Change
Fundamentals
Return on Equity
-85.61%
Trailing 12-Months
Asset Growth
-21.69%
Trailing 12-Months
Company Description
Moonlake Immunotherapeutics
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
MLTX Stock 12 Month Forecast
Average Price Target
$34.44
▲(87.81% Upside)
Technical Analysis
Ownership Overview
30.00% Insiders
1.83% Mutual Funds
0.23% Other Institutional Investors
67.20% Public Companies and
Individual Investors